EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC)

Jacek Rysz, Janusz Ławiński, Beata Franczyk, Anna Gluba-Sagr

International Journal of Molecular Sciences · 11.06.2025 · 26 (12) · 5577

DOI: 10.3390/ijms26125577 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.06.2025. Verfasst von Jacek Rysz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, 90-549 Lodz, Poland. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Immune Checkpoint Inhibitors, Kidney Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal cell carcinoma (RCC) accounts for about 403,000 new cases and 175,000 deaths worldwide each year. Clear cell RCC (ccRCC), the most prevalent subtype, is often driven by genetic mutations, such as VHL inactivation, leading to angiogenesis and immune escape. Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 have transformed treatment paradigms, yet therapeutic resistance remains a critical challenge. The immunosuppressive nature of the tumor microenvironment (TME) in ccRCC plays a central role in limiting ICI efficacy. Emerging strategies aim to overcome resistance by targeting key components of the TME, including tumor-associated macrophages, regulatory T cells (Tregs), and cytokine signaling. Agents such as nivolumab, pembrolizumab, and ipilimumab have demonstrated the ability to restore T-cell activity and mitigate immune suppression, offering clinical benefit in metastatic ccRCC. However, response rates vary, highlighting the need for rational combination therapies. ICIs combined with VEGF inhibitors have shown promising outcomes in clinical trials, and novel regimens continue to be explored. Risk stratification and personalized treatment selection are increasingly important as the therapeutic landscape evolves. This review synthesizes current advances in immunotherapy for ccRCC, with a focus on mechanisms of resistance and innovative strategies to enhance immune responsiveness. A deeper understanding of TME modulation and strategic combination approaches is essential to improve survival and quality of life for patients with advanced ccRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellImmune Checkpoint InhibitorsKidney NeoplasmsHumansTumor Microenvironment

Stichwörter der Autor:innen

PD-1 InhibitorsPD-L1 Inhibitorclinical trialsimmune checkpoint inhibitorsrenal cell carcinoma

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, 90-549 Lodz, Poland.
  • Department of Medicine, Faculty of Medicine, University of Rzeszow, 35-959 Rzeszow, Poland.

Zitieren

APA

Rysz, J., Ławiński, J., Franczyk, B., & Gluba-Sagr, A. (2025). Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC). International Journal of Molecular Sciences, 26(12), 5577. https://doi.org/10.3390/ijms26125577

Vancouver

Rysz J, Ławiński J, Franczyk B, Gluba-Sagr A. Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC). International Journal of Molecular Sciences. 2025;26(12):5577. doi:10.3390/ijms26125577

BibTeX
@article{Rysz2025,
  author = {Rysz, Jacek and Ławiński, Janusz and Franczyk, Beata and Gluba-Sagr, Anna},
  title = {Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC)},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {12},
  pages = {5577},
  doi = {10.3390/ijms26125577}
}
Kostenlos starten →